Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Prior treatment

• Patients has received PI3K inhibitor treatment before enrollment

Other illness

• Patients allergic to any of the study drugs；
• Patients with active infection；
• Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• Patients with a history of interstitial pneumonia, non infectious pneumonia, or highly suspected interstitial pneumonia;
• Patients with a history of neurological or psychiatric disorders, including epilepsy or dementia, in the past
• According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study.

Other

• Patients with CNS involvement, or with other neoplasm;
• Poor performance status, ECOG≥2;
• Patients in lactation or pregnancy；
• Patients (male or female) have the possibility of childbirth but are unwilling or have not taken effective contraceptive measures；

• Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria.
• refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients
• PET/CT or CT/MRI with at least one objectively evaluable lesion.
• Expected to survive more than 3 months.
• General status ECOG score 0-2 points.
• The laboratory test within 1 week before enrollment meets the following conditions:
  • Blood routine: WBC≥3×10e9/L, PLT≥75×10e9/L, ANC≥1.5×10e9/L. sCR≤1.5 mg/dL,GFR≥50 ml/min. Liver function: ALT \& AST≤3 times the upper limit of normal, TBIL ≤2 times the upper limit of normal.
  • Serum fibrinogen level≥1.0 g/L.
  • •Sign the informed consent form